CD4+ T follicular helper cells (T_{FH}) were assessed in adult patients with common variable immune deficiency (CVID) classified according to the presence of granulomatous disease (GD), autoimmunity (AI), or both GD and AI (Group I) or the absence of AI and GD (Group II). T_{FH} lymphocytes were characterized by expression of CXCR5 and PD-1. T_{FH} were higher (in both absolute number and percentage) in Group I than in Group II CVID patients and normal controls (N). Within CXCR5+CD4+ T cells, the percentage of PD-1(+) was higher and that of CCR7(+) was lower in Group I than in Group II and N. The percentages of Treg and T_{FH} reg were similar in both CVID groups and in N. T_{FH} responded to stimulation increasing the expression of the costimulatory molecules CD40L and ICOS as did N. After submitogenic PHA+IL-2 stimulation, intracellular expression of T_{FH} cytokines (IL-10, IL-21) was higher than N in Group I, and IL-4 was higher than N in Group II. These results suggest that T_{FH} are functional in CVID and highlight the association of increased circulating T_{FH} with AI and GD manifestations.

1. Introduction

Common variable immunodeficiency (CVID) comprises a heterogeneous group of diseases characterized by abnormal antibody production [1]. It is the most commonly diagnosed primary immunodeficiency, with an incidence of 1/10 000 to 1/50 000. It affects both sexes equally and the clinical manifestations may begin at any age [2–4]. Over 90% of the patients present with recurrent acute and sometimes chronic bacterial infections mainly of the respiratory and gastrointestinal tracts. Another feature of these patients is their major susceptibility for autoimmunity (AI) manifestations, granulomatous diseases (GD), and cancer [5–10]. Diagnosis of CVID is based on a significant decrease of IgG (at least two standard deviations below the mean for age) associated with a decrease of IgA and/or IgM isotypes, in patients older than 4 years of age and absence of isohemagglutinins and/or poor response to polysaccharide vaccines, with other defined causes of hypogammaglobulinemia excluded [2–4, II].

In most cases the etiology of CVID is not known. In a small percentage of patients, most families stranded, a few genetic defects have been described. These include mutations in genes coding for the inducible costimulator (ICOS) [12], CD19 [13, 14], CD20 [15], CD8 [16], and the B cell-activating factor receptor (BAFF-R) [17]. Eight to 10% of the patients carry mutations in the gene for the B cell receptor transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI). Similar mutations are found in unaffected relatives and normal controls, suggesting association but not causality [10, 18–23].

The process of acquiring an adequate antibody immune response is complex and involves specialized groups of T lymphocytes that interact with B lymphocytes in a tightly regulated way in the secondary lymphoid organs. This ultimately results in the generation of different immunoglobulin isotypes, memory effector, and regulatory cells. Failure at any of the stages of the process may lead to humoral immunodeficiency.

T follicular helper cells (T_{FH}) have a central role in the generation of the germinal center reaction (GC) which is necessary for the correct maturation of the humoral immune
response. Their absence or functional impairment generates defects in the assembly of B cell memory that lead to hypogammaglobulinemia. Most studies concerning the role of this T helper subset have been done in animal models, but in humans there is evidence that a group of CD4+ T cells expressing CXCR5 reflects Tfh present at the lymph nodes [24–26]. Programmed-death 1 (PD-1) is highly expressed in germinal center Tfh and its expression is induced after activation in CD4 and CD8 cells [27–29]. The inhibitory role of the PD-1/PD-ligand (PDL-1 or PDL-2) axis has been defined in relation to the T cell mediated response to antigens, but its role in the regulation of the B cell responses is less clear. While some studies report attenuated antibody responses where the PD-1/PDL-1 and PDL-2 interactions are prevented [30], others observed heightened immune responses in coincidence with increased Tfh numbers [31].

Circulating Tfh are phenotypically and functionally heterogeneous. A subgroup of Tfh with central memory/resting profile expressing chemokine receptor 7 (CCR7) predominates in normal individuals, while in patients with autoimmune conditions, Tfh with high expression of programmed-death 1 (PD-1) and low CCR7 are more abundant [32]. In addition, a subgroup of Tfh expressing both CXCR5 and FoxP3 (Tfh reg) that may suppress Tfh activity has been described [33]. Antibody deficiency and immune dysregulation in CVID could be related to absence or inefficient function of Tfh, to increased Tfh activity leading to downregulation of T/B cell cooperation for the synthesis of antibodies, or to interference with Tfh action due to other regulatory lymphocytes as CD8+ regulatory cells [34]. Based on these observations we decided to study the characteristics and function of Tfh in peripheral blood of adult CVID patients divided into two clinical phenotypes according to the presence or absence of autoimmunity (AI) and/or granulomatous disease (GD).

2. Material and Methods

2.1. Subjects. We reviewed the clinical and epidemiological data of our cohort of twenty-one adult patients with CVID. The diagnosis of CVID was made according to standard criteria [2,3], and all subjects were on monthly immunoglobulin replacement therapy. Based on patients' clinical records, we analyzed the age at onset of infectious symptoms, age at diagnosis, age at the time of the study, length of follow-up from CVID diagnosis to time of the study, and clinical manifestations. Patients were divided into two categories: Group I (n = 8), patients with AI, GD, or both, and Group II (n = 13), patients without these clinical manifestations.

Blood samples were drawn before the infusion of immunoglobulin. All studies were performed blinded to the clinical manifestations of the immunodeficiency. Controls (n = 19) were age related normal blood donors (N). This study was approved by the Ethics Committee of Academia Nacional de Medicina. All donors gave informed consent.

2.2. PBMC Isolation and Culture. Peripheral blood samples from all subjects were collected on heparin. PBMC were obtained by Ficoll-Hypaque (FH) centrifugation and suspended to 1 x 10⁶/mL in RPMI tissue culture medium containing 10% fetal calf serum (GIBCO, Grand Island, USA), streptomycin, and penicillin (RPMI-FCS). PBMC cultures were carried out in round bottom 5 mL polystyrene tubes (Falcon) containing 2 x 10⁶ PBMC that were suspended in 2 mL RPMI-FCS [35].

2.3. Cell Surface Phenotype of Mononuclear Cells from CVID Patients and N Controls. For assay of the different types of lymphocytes, flow cytometry techniques with a three-color assay were used. Aliquots of 100 μL heparinized peripheral blood were incubated with monoclonal antibodies and then were lysed using FACS Lysing solution (Becton Dickinson, San Jose, CA, USA) following the manufacturer's instructions. Analysis of surface markers was performed on a FACScan cytometer (Becton Dickinson, San Jose, CA, USA) and analyzed with FCS Express software. Lymphocytes were selected according to size (FSC) and side (SSC) scatter profiles. PBMC were also processed both before and after cell culture. Fluorescein isothiocyanate (FITC), phycoerythrin (PE), Alexa 488, or peridinin chlorophyll protein (PerCP) antibodies were purchased from BD Pharmingen, BD, and eBioscience (San Diego, CA, USA). Absolute numbers of the different lymphocytes were calculated taking into account the white cell count and the percentage of lymphocytes in May-Grünewald-Giemsa stained blood smears.

The phenotype of viable PBMC from CVID and N donors was analyzed before and after 2 or 7 days of PHA+IL-2 stimulated culture (performed as detailed below for the assay of cytokines). Lymphocyte viability was calculated taking into account the proportion of live lymphocytes in the SSC/FSC dot plots. Appropriate isotype controls were used to define the positive populations.

2.4. FoxP3+CD25+ T Cells (Treg) and FoxP3+CXCR5+ T Cells (Tfh reg). For Treg and Tfh reg determination, PBMC were stained with PerCP anti-CD4 and FITC anti-CD25 or PerCP anti-CD4 and Alexa 488 anti-CXCR5. Then they were fixed and permeabilized with Fix and Perm (Caltag Laboratories, Burlingame, California, USA) according to the manufacturer's instructions. After permeabilization they were reacted with PE anti-FoxP3 (clone PCH101, eBioscience, San Diego, CA, USA).

2.5. Costimulatory Molecules (CD40L and ICOS) and Intracellular IL-10, IL-21, and IL-4 in CVID and N. PBMC
3.1. CVID Patients.

We analyzed data on 11 male and 10 female CVID patients; the mean age of patients at the time of the study was 49.9 ± 15.8 years (range 21 to 73), median 38.5. The age at onset of disease was available for 15 patients, one patient did not have infections, and mean age was 19.4 ± 15.2 years (range 1 to 50), median 19. Mean age at diagnosis was 35.4 ± 18.2 years (range 13 to 70), median was 31.5 years, and mean follow-up duration was 10.6 ± 7.8 years (range 1 to 24), median 10.5. All patients were on gammaglobulin replacement therapy since diagnosis.

Patients were divided into two categories, Group I, eight patients, and Group II, 13. The clinical and epidemiological data of Group I patients are shown in Table I. Patients 4 and 5 had AI disease manifestations 13 and 33 years, respectively, before the onset of infectious symptoms. With the exception of patient 1 that was studied under steroid and infliximab treatment [37], none of the patients in Group I received systemic steroids, standard immunosuppressive therapies, or biologic agents at the time of the study.

3.2. Absolute Values of T and B Lymphocytes in CVID and N.

The total number of lymphocytes, CD4+ T cells, and CD8+ T cells (CXCR5+CD4+) was measured in peripheral blood from CVID patients, right before IV immunoglobulin replacement. As shown in Figure 1, the number of CD4+ lymphocytes was not significantly different in both CVID groups compared to N, but TFH cells were elevated, especially in Group I patients (Figure I(a)).

In Group I patients the absolute number of CD19+ cells correlated with that of TFH cells suggesting a link in the regulation of these two cell populations (Figure I(b)). There was no significant correlation between CD19+ cells and TFH in Group II and N. A similar analysis was performed between the absolute number of CD27+CD19+ and those of TFH cells. We found significant correlation only in Group I of patients.

In 2/8 Group I patients and in 6/13 of Group II patients, the percentage of CD19+ B lymphocytes (1.6 to 4.71%) was below normal (N% CD19+, mean + SD: 9.93 ± 3.21, n = 15).

3.3. Follicular T Lymphocytes (TFH), TFH Subpopulations, Treg, and TFH reg in CVID and N.

Because CD4 lymphocytes provide essential help for the maturation of B cell memory, we further analyzed the expression of markers associated with the maturation of B cell memory. We studied the expression of markers of the plasma cell differentiation (CXCR5, CD138) and Tfh, including TCR δ and TCR γ, and found that both the CD19+ and CD8+ T lymphocytes were significantly elevated in CVID Group I compared to N (p < 0.05). Further, there was a significant correlation between the absolute number of CD19+ B lymphocytes and the percentage of CD4+ T lymphocytes expressing CXCR5, CD138, and TCR δ.

### Table 1: Clinical and epidemiological data of Group I patients.

| Patient | Sex | Age (years) | Age at onset (years) | Age at Dx. (years) | Follow up D. (years) | GD | AI |
|---------|-----|-------------|----------------------|-------------------|---------------------|----|----|
| 1       | F   | 65          | 31                   | 41                | 24                  | LIP, LN | Hypothyroidism |
| 2       | M   | 36          | 1                    | 13                | 23                  |     | AHA |
| 3       | F   | 21          | 16                   | 17                | 4                   |     | ITP, AHA |
| 4       | M   | 69          | 50                   | 66                | 3                   | Lung, bowel | ITP |
| 5       | F   | 69          | ND                   | ND                | 3                   |     |     |
| 6       | F   | 36          | ND                   | 20                | 16                  |     | E N |
| 7       | M   | 30          | ND                   | 14                | 16                  |     | ALOP |
| 8       | F   | 59          | 25                   | 43                | 16                  |     | AHA, N |

LN: lymph node; LIP: Lymphocytic interstitial pneumonia. LIP diagnoses were made by pathological examination in patients #1, #2 and #7. LIP in patient #4 was established by CAT scan. AHA: autoimmune hemolytic anemia; ALOP: alopecia areata; ITP: immune thrombocytopenia; EN: erythema nodosum; N: autoimmune neutropenia.
with follicular helper T cells (CXCR5 and PD-1) in CD4 lymphocytes. The results shown in Figure 2 demonstrate that the percentage of CXCR5+CD4+ T cells was higher in Group I CVID patients when compared to those of Group II and N. Regarding Group II CVID patients, there were no significant differences when compared to N. Concerning coexpression of PD-1 and CXCR5, the highest values were observed in CVID patients with a GD and/or AI disease phenotype (Group I).

In some patients the studies could be repeated after 12–24 months and the CXCR5+PD-1+ percentages in the CD4 region remained high (patient #CM initial value: 23.28%; after 24 months: 25.91%; after 26 months: 25.32%; patient #PV initial value: 15.5%; after 12 months: 18.39%; after 14 months: 16.38%).

Because low CCR7 and high PD-1 expression have been observed in circulating T_{FH} from patients with autoimmune

Figure 1: T_{FH} and B lymphocyte absolute values in CVID and N. (a) Absolute lymphocyte values (cells/mm³) were calculated in CVID Group I, n = 8 (I), and Group II, n = 13 (II), patients and control donors (N), n = 19. Peripheral blood was stained with monoclonal antibodies and absolute values of viable CD4+ T lymphocytes and CD4+ T cells coexpressing CXCR5 (T_{FH}) were calculated after analysis on a FACScan Becton Dickinson flow cytometer. (b) A comparison between peripheral blood viable B lymphocytes (CD19+ cells), memory B lymphocytes (CD27+CD19+ cells), and T_{FH} values (CXCR5+CD4+ cells) was done in CVID Group I, Group II, and N controls. Lineal regression analysis was consigned in the graphs. Only in Group I was the correlation statistically significant.

...
conditions, we examined the T\textsubscript{FH} subsets considering the level of expression of these molecules on the surface of CXCR5+CD4+ T cells from CVID patients and N controls. The results shown in Figure 3 demonstrate that high PD-1 and low CCR7 expression were the rule in Group I compared to Group II and N. PD-1 was also higher than N in Group II but CCR7 values did not differ from those of N.

The percentages of Treg (CD25+ Foxp3+/CD4) and T\textsubscript{FH} reg (CXCR5+ Foxp3+/CD4) within the CD4+ T lymphocyte region were similar in both CVID groups and in N (mean ±
Figure 3: CCR7 and PD-1 expression in T_{FH} of CVID patients. The percentage of CCR7+ cells within the CXCR5+CD4+ T lymphocyte region was calculated for CVID Group I and Group II patients and N (% CXCR5+CCR7+/CXCR5+) (a). Likewise, the percentage of PD-1+ cells in the CXCR5+CD4+ T lymphocyte region was determined (CXCR5+PD-1+/CXCR5+) (b). Statistical differences are consigned in the graph.

3.4. Upregulation of Costimulatory Molecules CD40L and ICOS in CVID and N. Defects in the expression of costimulatory molecules on CD4 lymphocytes could underlie the lack of an adequate humoral response. Therefore we examined CD40L and ICOS expression on CD4 T lymphocytes and CXCR5+CD4+ T lymphocytes after 2 days of culture either nonstimulated (medium) or with PHA+IL-2 stimulation (PHA+IL-2). After T cell stimulation, expression of both CD40L and ICOS could be induced in CD4 cells and in CXCR5+CD4+ T lymphocytes from CVID patients to a similar extent to N (Table 2).

3.5. IL-10, IL-21, and IL-4 Induction by T Cell Stimuli in CVID and N. Although other subtypes of T helper lymphocytes can synthesize these cytokines, human T_{FH} produce abundant IL-21 and IL-10 upon stimulation. IL-4 is also a CD4-derived cytokine involved in the process of antibody generation and it can be produced by Th2 CD4 lymphocytes and by the Th2 subset of T_{FH} [24]. In order to assess the ability of CD4 T cells to produce these cytokines, PBMC were stimulated with a submitogenic dose of PHA and IL-2. The percentage of CD4 T cells with intracellular IL-10, IL-21, or IL-4 was recorded. The percentage of IL-10+ and IL-21+ CD4+ T cells was higher than N in CVID Group I and Group II after PHA stimulation while IL-4+ CD4+ T cells were not different to N in both CVID groups. When considering cytokine (IL-10, IL-21, and IL-4) expression by CD4+CXCR5+ T cells (T_{FH}), it was similar in both groups of CVID to that of N. However, when cytokine expression (IL-10 and IL-21) was analyzed in CD4+ T cells that did not express CXCR5, it was significantly higher (p < 0.029) in both CVID groups than in N (Figures 4(a) and 4(b)). IL-4 expression was higher than N (p = 0.036) in CXCR5−CD4+ T cells (Figure 4(c)) in Group II patients.

4. Discussion

It is difficult to determine the immunopathogenic importance and/or predictive value of different laboratory findings in relation to clinical manifestations in adult CVID. Attempts to correlate clinical observations with laboratory data has led to different classifications that take into account serum immunoglobulin levels, flow cytometry characteristics of CVID B lymphocytes, or B lymphocyte function [38]. Pheno-typing of B cell subpopulations has confirmed the reduction of switched memory B cells (IgM-IgD-CD27+CD19+) in association with splenomegaly or granulomatous disease [38]. Changes in the proportion of other subgroups of B lymphocytes have also been described in CVID [39–41].

We have now studied a series of adult CVID patients, trying to correlate clinical findings with some characteristics of the peripheral blood T lymphocyte phenotype. Patients were divided in two groups: those who had evidence of AI disease or GD (Group I) and those who did not (Group II).

Because T_{FH} are important for the setup of a correct antibody response, we have focused on this helper T cell subpopulation in relation to the occurrence of immune dysregulation associated with GD or AI disease. Interestingly, we observed that the number of CXCR5+CD4+ T cells was significantly related to the number of CD19+ B lymphocytes, in Group I patients (with a similar tendency in N), suggesting that there may be a link in the regulation of the number of these lymphocytes.

Our results clearly show that the T_{FH} population was expanded in both groups of CVID patients, but CXCR5 and PD-1 coexpression was higher in Group I than in Group II and N. PD-1 is a potent inhibitory receptor important for T cell tolerance and it has been associated with CD8 T cell exhaustion during chronic viral infection [7, 28, 42]. A subgroup of T_{FH} defined by high PD-1 and low CCR7 expression has been demonstrated in patients with autoimmune conditions [32]. These cells seem to be the counterpart of active effector CD4 T cells within the T_{FH} compartment.
on T cells. The immunologic dysregulation leads to skewing of blood CXCR5+ T cells from CVID patients. In this regard, an important role of IL-21 (either from TFH cells or from other cell sources) as a player in the differentiation of Th17 cells that are important in autoimmunity has been recently proposed [47]. It is possible that an IL-21-stimulated Th17 response could play a role in the generation of AI or EG in CVID patients. Because TFH cells comprise a heterogeneous group of cells, increased circulating CXCR5+CD4+ T lymphocytes might not reflect their ability to cooperate with antibody production. Tfh1-Tfh2 are required for adequate antibody synthesis, while Tfh1-Tfh2 are not [24]. The fact that after stimulation with PHA CXCR5+CD4+ T cells from CVID patients produced IL-4 in addition to IL-21 and IL-10 indicates that lack of Tfh1-Tfh2 was not the cause of the immunologic defect in this case.

High Tfh in circulation has also been reported in some autoimmune conditions [48] and this is interesting in relation to the increased occurrence of autoimmune phenomena in CVID. Indeed, in juvenile dermatomyositis (JDM), immune dysregulation leads to skewing of blood CXCR5+ Tfh cells towards Tfh2 and Tfh1-Tfh2 [24], while in JDM and other autoimmune conditions as systemic lupus erythematosus (SLE) or Sjogren’s disease, increased levels of functional CXCR5+CD4+ T cells lead to hypergammaglobulinemia and autoantibody synthesis [49–51] in CVID hypogammaglobulinemia or selected immunoglobulin deficiency occurs, probably as a result of impaired B cell maturation [52]. On the other hand, repeated infections or continuous activation of the inflammatory response [53] could also determine the Tfh increase, since circulating Tfh with an active effector profile

| Table 2: Expression of costimulatory molecules (CD40L and ICOS) in PHA+IL-2 stimulated PBMC from CVID patients and N. |
|---------------------------------------------------------------|
| **Costimulatory molecules expression in CD4+ lymphocytes (%, mean ± SE)** |
| CD40L+ | CCR5+CD40L+ | ICOS | CCR5+ICOS+ |
| **Group I (n=4)** |
| Medium | 1.8 ± 2 | 1.7 ± 1.2 | 3.0 ± 0.2 | 2.2 ± 1.7 |
| PHA+IL-2 | 11.0 ± 3.7 | 9.4 ± 3.5 | 24.4 ± 8.2 | 17.0 ± 5.3 |
| **Group II (n=4)** |
| Medium | 2.4 ± 2 | 1.9 ± 1.1 | 4.3 ± 1.8 | 3.0 ± 1.7 |
| PHA+IL-2 | 11.5 ± 4.1 | 10.3 ± 4.2 | 22.8 ± 9.0 | 15.6 ± 6.5 |
| **Normals (n=7)** |
| Medium | 2.3 ± 1.5 | 2.0 ± 1.3 | 2.8 ± 3.2 | 1.8 ± 0.9 |
| PHA+IL-2 | 7.3 ± 1.5 | 6.4 ± 1.5 | 16.3 ± 1.8 | 7.2 ± 1.1 |

PBMC were stimulated with 2.5 μg/mL phytohemmagglutinin and 5 UI/mL interleukin-2 for 2 days and then were stained with anti-CD4, anti-CXCR5 and either anti-CD40L or anti-ICOS. The percentage of CD4+ cells that express CD40L, CXCR5 plus CD40L, ICOS and CXCR5 plus ICOS is consigned. No significant differences were observed between both CVID groups and Normals.
Figure 4: Intracellular cytokines after PHA+IL-2 stimulation of PBMC in CVID and N. The percentage of intracellular cytokines ((a) IL-10, (b) IL-21, and (c) IL-4) in permeabilized CD4+ T cells (CXCR5+ and CXCR5−) was determined after 7 days of PHA+IL-2 stimulation in CVID Group I \( (n=4) \), Group II \( (n=4) \), and N \( (n=6) \). Statistical differences are consigned in the graph. White bars represent unstimulated controls.

(high PD-1, low CCR7) were highest in patients with GD, AI, or both GD and AI manifestations.

5. Conclusions

Our results demonstrate that circulating \( T_{FH} \) are higher than normal in adult CVID patients. \( T_{FH} \) were able to respond to stimulation upregulating costimulatory molecules and providing the appropriate B helping cytokines. This suggests that intrinsic functional \( T_{FH} \) defects are not the primary cause of CVID. Moreover, increased levels of circulating \( T_{FH} \) highlight the relationship of CVID with other autoimmune diseases.

Abbreviations

CVID: Common variable immune deficiency
\( T_{FH} \): T follicular helper cells
GD: Granulomatous disease
AI: Autoimmunity
ICOS: Inducible costimulator
\( T_{FH} \) reg: Regulatory T follicular helper cells.

Competing Interests

None of the authors has any potential financial competing interests related to this paper.


Authors’ Contributions

Ana Coraglia and Nora Galassi equally contributed to the paper. Ana Coraglia and Nora Galassi performed experiments and interpreted, analyzed, and wrote the paper; Marta Felippo performed experiments; Diego S. Fernández Romero, M. Cecilia Juri, and Alejandro Malbrán were in charge of diagnosis and assistance of the patients and discussed laboratory results; María M. E. de Bracco designed and directed the study and wrote the paper.

Acknowledgments

The authors acknowledge the assistance of Dr. N. Riera and M. Belén Irigoyen of the Cytometry Laboratory-IMEX. This work was supported by grants from ANPCYT-SECYT and CONICET PIP 11220100100032, Buenos Aires, Argentina, and by Fundacion Rene Baron, Buenos Aires, Argentina.

References

[1] M. E. Conley, L. D. Notarangelo, and A. Etzioni, “Diagnostic criteria for primary immunodeficiencies,” Clinical Immunology, vol. 93, no. 3, pp. 190–197, 1999.
[2] International Union of Immunological Societies, “Primary immunodeficiency diseases report of an IUIS scientific committee,” Clinical & Experimental Immunology, vol. 118, supplement 1, pp. I–8, 1999.
[3] F. A. Bonilla, I. L. Bernstein, D. A. Khan et al., “Practice parameter for the diagnosis and management of primary immunodeficiency,” Annals of Allergy, Asthma & Immunology, vol. 94, supplement 1, pp. S1–S63, 2005.
[4] A. A. Bousfiha, L. Jeddane, F. Ailal et al., “A phenotypic approach for IUIS PID classification and diagnosis: guidelines for clinicians at the bedside,” Journal of Clinical Immunology, vol. 33, no. 6, pp. 1078–1087, 2013.
[5] R. A. Hermaszewski and A. D. Webster, “Primary hypogammaglobulinemia: a survey of clinical manifestations and complications,” Quarterly Journal of Medicine, vol. 86, no. 1, pp. 31–42, 1993.
[6] C. Cunningham-Bundles and C. Bodian, “Common variable immunodeficiency: clinical and immunological features of 248 patients,” Clinical Immunology, vol. 92, no. 1, pp. 34–48, 1999.
[7] I. Quinti, A. Soresina, G. Spadaro et al., “Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency,” Journal of Clinical Immunology, vol. 27, no. 3, pp. 308–316, 2007.
[8] E. Oksenhendler, L. Gérard, C. Fieschi et al., “Infections in 252 patients with common variable immunodeficiency,” Clinical Infectious Diseases, vol. 46, no. 10, pp. 1547–1554, 2008.
[9] H. Chapel, M. Lucas, M. Lee et al., “Common Variable immunodeficiency disorders: division into distinct clinical phenotypes,” Blood, vol. 112, no. 2, pp. 277–286, 2008.
[10] A. Durandy, S. Kracker, and A. Fischer, “Primary antibody deficiencies,” Nature Reviews Immunology, vol. 13, no. 7, pp. 519–533, 2013.
[11] L. Bezrodnik, M. I. Gaillard, and D. Carelli, “Clinical and immunological assessment of 94 patients with primary humoral immunodeficiency: common variable immunodeficiency, selective IgA deficiency and polysaccharide antibody deficiency syndrome,” Journal of Pediatric Infectious Diseases, vol. 6, no. 3, pp. 159–166, 2011.
[12] B. Grimbacher, K. Warnatz, and H.-H. Peter, “The immunological synapse for B-cell memory: the role of the ICOS and its ligand for the longevity of humoral immunity,” Current Opinion in Allergy and Clinical Immunology, vol. 3, no. 6, pp. 409–419, 2003.
[13] M. C. van Zelm, I. Reisli, M. Van Der Burg et al., “An antibody-deficiency syndrome due to mutations in the CD19 gene,” New England Journal of Medicine, vol. 354, no. 18, pp. 1901–1912, 2006.
[14] H. Kanegane, K. Agematsu, T. Futatani et al., “Novel mutations in a Japanese patient with CD19 deficiency,” Genes and Immunity, vol. 8, no. 8, pp. 663–670, 2007.
[15] T. W. Kuipers, R. J. Bende, P. A. Baars et al., “CD20 deficiency in humans results in impaired T cell-independent antibody responses,” Journal of Clinical Investigation, vol. 120, no. 1, pp. 214–222, 2010.
[16] M. C. van Zelm, J. Smet, B. Adams et al., “CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency,” The Journal of Clinical Investigation, vol. 120, no. 4, pp. 1265–1274, 2010.
[17] K. Warnatz, U. Salzer, M. Rizzi et al., “B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 33, pp. 13945–13950, 2009.
[18] U. Salzer, H. M. Chapel, A. D. B. Webster et al., “Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans,” Nature Genetics, vol. 37, no. 8, pp. 820–828, 2005.
[19] E. Castigli, S. A. Wilson, L. Garibyan et al., “TACI is mutant in common variable immunodeficiency and IgA deficiency,” Nature Genetics, vol. 37, no. 8, pp. 829–834, 2005.
[20] Q. Pan-Hammarström, U. Salzer, L. Du et al., “Re-examining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency,” Nature Genetics, vol. 39, no. 4, pp. 429–430, 2007.
[21] U. Salzer, C. Bacchelli, S. Buckridge et al., “Relevance of biallelic versus monoallelic TNFRSF13B mutation variants,” Blood, vol. 113, no. 9, pp. 1967–1976, 2009.
[22] M. E. Conley, “Genetics of hypogammaglobulinemia: what do we really know?” Current Opinion in Immunology, vol. 21, no. 5, pp. 466–471, 2009.
[23] M. B. Almejnún, E. Sajaroff, M. Galicchio et al., “Immunological characteristics and two novel mutations in TACI in a cohort of 28 pediatric patients with common variable immunodeficiency,” Journal of Clinical Immunology, vol. 32, no. 1, pp. 89–97, 2012.
[24] R. Morita, N. Schmitt, S.-E. Bentebibel et al., “Human blood CXCR5+CD4+ T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion,” Immunity, vol. 34, no. 1, pp. 108–121, 2011.
[25] L. Bossaller, J. Burger, R. Draeger et al., “ICOS deficiency is associated with severe reduction of CXCR5+ CD4 germinal center Th cells,” The Journal of Immunology, vol. 177, no. 7, pp. 4927–4932, 2006.
[26] N. Simpson, P. A. Gatenby, A. Wilson et al., “Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 62, no. 1, pp. 234–244, 2010.
[27] M. E. Keir, M. J. Butte, G. J. Freeman, and A. H. Sharpe, "PD-1 and its ligands in tolerance and immunity," Annual Review of Immunology, vol. 26, pp. 677–704, 2008.

[28] S. D. Blackburn, H. Shin, W. N. Haining et al., "Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection," Nature Immunology, vol. 10, no. 1, pp. 29–37, 2009.

[29] D. M. Dorfman, J. A. Brown, A. Shahsafaei, and G. J. Freeman, "Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma," The American Journal of Surgical Pathology, vol. 30, no. 7, pp. 802–810, 2006.

[30] K. L. Good-Jacobson, C. G. Szumilas, L. Chen, A. H. Sharpe, M. M. Tomayko, and M. J. Shlomchik, "PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells," Nature Immunology, vol. 11, no. 6, pp. 535–542, 2010.

[31] E. Hams, M. J. McCarron, S. Amu et al., "Blockade of B7-H1 (programmed death ligand 1) enhances humoral immunity by positively regulating the generation of T follicular helper cells," Journal of Immunology, vol. 186, no. 10, pp. 5648–5655, 2011.

[32] J. He, L. M. Tsai, Y. A. Leong et al., "Circulating precursor CCR7lo PD-1hi CXCR5lo CD4+ T cells indicate Th1 cell activity and promote antibody responses upon antigen reexposure," Immunity, vol. 39, no. 4, pp. 770–781, 2013.

[33] M. A. Linterman, P. Pierson, S. K. Lee et al., "Foxp3+ follicular regulatory T cells control the germinal center response," Nature Medicine, vol. 17, no. 8, pp. 975–982, 2011.

[34] A. Noble, A. Giorgini, and J. A. Leggat, "Cytokine-induced IL-10–secreting CD8 T cells represent a phenotypically distinct suppressor T-cell lineage," Blood, vol. 107, no. 11, pp. 4475–4483, 2006.

[35] B. Ruibal-Ares, L. Belmonte, P. Baré et al., "Monocyte differentiation and HIV replication after prolonged culture of peripheral blood mononuclear cells from HIV-infected individuals," Cellular Immunology, vol. 210, no. 1, pp. 11–20, 2001.

[36] A. Coriglia, M. Filippo, P. Schierloh, A. Malbran, and M. M. de E de Bracco, "CD4+ T lymphocytes with follicular helper phenotype (ThFp) in patients with SH2D1A deficiency (XLP)," Clinical Immunology, vol. 141, no. 3, pp. 357–364, 2011.

[37] A. Malbrán, M. C. Juri, and D. S. Fernández Romero, "Common variable immunodeficiency and granulomatous disease treated with infliximab," Clinical Immunology, vol. 134, no. 3, pp. 359–360, 2010.

[38] C. Wehr, T. Kivioja, C. Schmitt et al., "The EUROclass trial: defining subgroups in common variable immunodeficiency," Blood, vol. 113, no. 1, pp. 77–85, 2009.

[39] K. Warnatz, A. Denz, R. Dräger et al., "Severe deficiency of switched memory B cells (CD27−IgM+ IgD−) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease," Blood, vol. 99, no. 5, pp. 1544–1551, 2002.

[40] M. Rakhmanov, B. Keller, S. Gutenberger et al., "Circulating CD21 low B cells in CVID resemble tissue homing, innate-like B cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 32, pp. 13451–13456, 2009.

[41] I. Isnardi, Y.-S. Ng, L. Menard et al., "Complement receptor 2/CD21- human naïve B cells contain mostly autoreactive unresponsive clones," Blood, vol. 115, no. 24, pp. 5026–5036, 2010.

[42] D. L. Barber, E. J. Wherry, D. Masopust et al., "Restoring function in exhausted CD8 T cells during chronic viral infection," Nature, vol. 439, no. 7077, pp. 682–687, 2006.

[43] P. T. Sage, L. M. Francisco, C. V. Carman, and A. H. Sharpe, "The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood," Nature Immunology, vol. 14, no. 2, pp. 152–161, 2013.

[44] V. Thon, H. M. Wolf, M. Saggary et al., "Defective integration of activating signals derived from the T cell receptor (TCR) and costimulatory molecules in both CD4+ and CD8+ T lymphocytes of common variable immunodeficiency (CVID) patients," Clinical and Experimental Immunology, vol. 110, no. 2, pp. 174–181, 1997.

[45] M. B. Fischer, I. Hauber, H. Eggenbauer et al., "A defect in the early phase of T-cell receptor-mediated T-cell activation in patients with common variable immunodeficiency," Blood, vol. 84, no. 12, pp. 4234–4241, 1994.

[46] V. Thon, H. Eggenbauer, H. M. Wolf et al., "Antigen presentation by common variable immunodeficiency (CVID) B cells and monocytes is unimpaired," Clinical and Experimental Immunology, vol. 108, no. 1, pp. 1–8, 1997.

[47] E. K. Deenick and S. G. Tangye, "IL-21: a new player in Th17-cell differentiation," Immunology and Cell Biology, vol. 86, no. 5, p. 478, 2008.

[48] D. Yu and C. G. Vinuesa, "Multiple checkpoints keep follicular helper T cells under control to prevent autoimmunity," Cellular and Molecular Immunology, vol. 7, no. 3, pp. 198–203, 2010.

[49] M. A. Linterman, R. J. Rigby, R. K. Wong et al., "Follicular helper T cells are required for systemic autoimmunity," Journal of Experimental Medicine, vol. 206, no. 3, pp. 561–576, 2009.

[50] J. S. Weinstein, S. G. Hernandez, and J. Craft, "T cells that promote B-Cell maturation in systemic autoimmunity," Immunological Reviews, vol. 247, no. 1, pp. 160–171, 2012.

[51] L. D. DiPlacido and J. Craft, "Emerging from the shadows: follicular helper T cells in autoimmunity," Arthritis and Rheumatism, vol. 62, no. 1, pp. 6–8, 2010.

[52] M. G. Seidel, "Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment," Blood, vol. 124, no. 15, pp. 2337–2344, 2014.

[53] H.-J. Ko, H. Yang, J.-Y. Yang et al., "Expansion of Th17-like cells during chronic Salmonella exposure mediates the generation of autoimmune hypergammaglobulinemia in MyD88-deficient mice," European Journal of Immunology, vol. 42, no. 3, pp. 618–628, 2012.